CEO COMMENTS

Kristina Torfgård comments Q2 report 2026

“During the period, IRLAB took several important steps forward: the drug candidate IRL757 was assigned the international nonproprietary name (INN) linepemat, an integrated analysis confirmed mesdopetam’s efficacy profile ahead of Phase III, and a successful capital raise strengthened the company’s financial position. With a strengthened cash position, the company is now aiming to bring the ongoing partner discussions to a conclusion during the year and deliver results from the Phase Ib study LIFT-PD in mid-2027.

With the clear priorities we established at the beginning of 2026 and a strengthened financial position, I look forward to leading the company toward upcoming milestones and working purposefully to realize the potential within our project portfolio.”

Our strategic priorities:

• Partnerships and financing — continue and deepen discussions with potential collaborators, licensees, and investors to secure funding for development programs and support the company’s long-term growth.
• IRL1117 — advance preclinical development activities with the goal of making the project Phase I-ready
• Linepemat (IRL757) — execute the ongoing Phase Ib clinical study in close collaboration with Otsuka, evaluate the results and determine the strategy for the next stage in development.
• Mesdopetam — secure funding for the Phase III program through strategic partnerships or licensing agreements.
• Pirepemat — implement the long-term development strategy and prepare for the next clinical study.

LATEST INTERIM REPORTS

LATEST ANNUAL REPORT